2010
Role of dual PI3/Akt and mTOR inhibition in Waldenström's Macroglobulinemia
Oncotarget
Epigenetic modifications as key regulators of Waldenström's Macroglobulinemia biology
Journal of Hematology & Oncology
microRNA-dependent modulation of histone acetylation in Waldenström Macroglobulinemia
Blood
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed Multiple Myeloma
Blood
Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia
American Journal of Hematology
Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom Macroglobulinemia
Blood
Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed/refractory Waldenström Macroglobulinemia
Journal of Clinical Oncology
Clinical and translational studies of a phase II trial of the novel oral AKT inhibitor perifosine in relapsed or relapsed/refractory Waldenström’s Macroglobulinemia
Clinical Cancer Research
Dual targeting of the PI3K/Akt/mTOR pathway as an anti-tumor strategy in Waldenström’s Macroglobulinemia
Blood
Role of dual PI3/Akt and mTOR inhibition in Waldenström's Macroglobulinemia
Oncotarget
Epigenetic modifications as key regulators of Waldenström's Macroglobulinemia biology
Journal of Hematology & Oncology
microRNA-dependent modulation of histone acetylation in Waldenström Macroglobulinemia
Blood
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed Multiple Myeloma
Blood
Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia
American Journal of Hematology
Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom Macroglobulinemia
Blood
Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed/refractory Waldenström Macroglobulinemia
Journal of Clinical Oncology
Clinical and translational studies of a phase II trial of the novel oral AKT inhibitor perifosine in relapsed or relapsed/refractory Waldenström’s Macroglobulinemia
Clinical Cancer Research
Dual targeting of the PI3K/Akt/mTOR pathway as an anti-tumor strategy in Waldenström’s Macroglobulinemia
Blood